Latest action: Referred to the House Committee on Energy and Commerce.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Bill supports research and care programs for blood cancer patients.
The problem
Blood cancer patients need better treatment options, research funding, and access to care. Current support may be insufficient for prevention and patient services.
The proposal
Establishes programs to fund blood cancer research, improve patient access to treatment, and support clinical trials and educational initiatives.
The impact
Blood cancer patients, researchers, and healthcare providers benefit from increased funding. Some taxpayers may see higher costs to fund new programs.
Funding blood cancer research can lead to new treatments and cures. Better research may improve survival rates and quality of life for patients. Scientific progress benefits future generations.
Expands care programs so more patients can receive treatment. Reduces financial barriers for people fighting blood cancer. Helps uninsured and underinsured patients get needed services.
Enables more patients to participate in experimental treatments. Speeds up development of new therapies. Gives patients hope for better treatment options.
Funding supports education and training for blood cancer specialists. Creates jobs in research and healthcare. Builds long-term capacity to treat these diseases.
New programs require taxpayer funding and add to the budget. Costs may be substantial depending on program scope. Could increase national debt without offsetting cuts or revenue.
No guarantee that research funding will produce breakthrough treatments quickly. Some programs may not achieve promised results. Success of healthcare spending varies widely.
Focuses only on blood cancer while other diseases also need research funding. May not address root causes of healthcare costs. Other cancer types and diseases compete for resources.
New programs require government coordination and oversight. Administrative costs may reduce funds reaching patients. Delays in program launch could slow benefits.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.